His primary areas of study are Immunology, Chimeric antigen receptor, Antigen, Immunotherapy and T cell. His Immunology research incorporates themes from Cytotoxic T cell and Interleukin 12. His Chimeric antigen receptor study integrates concerns from other disciplines, such as Tumor microenvironment, Oncology and B cell.
The Antigen study combines topics in areas such as Cancer, Internal medicine, Clinical trial and Car t cells. His studies in Immunotherapy integrate themes in fields like CD28, Receptor and T-cell receptor. His research links Cancer research with T cell.
His primary areas of investigation include Chimeric antigen receptor, Immunology, Cancer research, Antigen and T cell. Renier J. Brentjens studied Chimeric antigen receptor and Adoptive cell transfer that intersect with Hematopoietic stem cell transplantation. In his study, which falls under the umbrella issue of Immunology, Refractory is strongly linked to Oncology.
His biological study spans a wide range of topics, including Car t cells, Leukemia, Immune checkpoint and CD40. His Antigen research incorporates elements of Cancer, Receptor, Antibody and Immune system. The T cell study combines topics in areas such as Molecular biology, CD8, Cell therapy and B cell.
Renier J. Brentjens spends much of his time researching Chimeric antigen receptor, Cancer research, Immunotherapy, Antigen and Internal medicine. His Chimeric antigen receptor study combines topics from a wide range of disciplines, such as Receptor, Cytokine, Multiple myeloma and Cell biology. Renier J. Brentjens has researched Cancer research in several fields, including Immune system, Tyrosine-kinase inhibitor, Safety profile, Interleukin 12 and Refractory Mantle Cell Lymphoma.
His work carried out in the field of Immunotherapy brings together such families of science as Tumor microenvironment, Ovarian cancer and Genetic enhancement. His Antigen research is multidisciplinary, incorporating perspectives in Immune checkpoint, T cell and Cell therapy. As part of one scientific family, he deals mainly with the area of Internal medicine, narrowing it down to issues related to the Oncology, and often CD19, MEDLINE, Adult Acute Lymphoblastic Leukemia and B Acute Lymphoblastic Leukemia.
Renier J. Brentjens mainly investigates Antigen, Immunotherapy, Chimeric antigen receptor, Internal medicine and Cancer research. His Antigen study combines topics in areas such as Receptor and Multiple myeloma. He specializes in Immunotherapy, namely CAR T-cell therapy.
His Chimeric antigen receptor research includes elements of Salvage therapy, Subsequent Relapse, Diffuse large B-cell lymphoma and Oncology. The study incorporates disciplines such as Proinflammatory cytokine, Interleukin 12, Cytokine secretion and Genetic enhancement in addition to Cancer research. The concepts of his Lymphoma study are interwoven with issues in Chemotherapy, Gastroenterology, White blood cell, Cytopenia and Chimeric Antigen Receptor T-Cell Therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido.
Science Translational Medicine (2014)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens;Marco L. Davila;Isabelle Riviere;Jae Park.
Science Translational Medicine (2013)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park;Isabelle Rivière;Mithat Gonen;Xiuyan Wang.
The New England Journal of Medicine (2018)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain;Renier Brentjens;Isabelle Rivière.
Cancer Discovery (2013)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens;Isabelle Rivière;Jae H. Park;Marco L. Davila.
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil;Eric L. Smith;Renier J. Brentjens;Jedd D. Wolchok.
Nature Reviews Clinical Oncology (2016)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
John Maher;Renier J Brentjens;Gertrude Gunset;Isabelle Rivière.
Nature Biotechnology (2002)
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
Renier J. Brentjens;Jean Baptiste Latouche;Elmer Santos;Francesc Marti.
Nature Medicine (2003)
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram;James C. Lee;Erik G. Hayman;Gavin H. Imperato.
Toxicity and management in CAR T-cell therapy.
Challice L Bonifant;Hollie J Jackson;Renier J Brentjens;Kevin J Curran.
Molecular Therapy - Oncolytics (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: